Skip to content
Screener

Solid Biosciences Inc. SLDB Net margin

Discontinued — last reported Q4 '22

Net margin at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-6.9%—
Biogen logo
BiogenBIIB
8.8%-6.5pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
21.6%+8.9pp
Insmed logo
InsmedINSM
-76.9%-31.8pp
Regenxbio logo
RegenxbioRGNX
-112.6%-0.1pp
PTC Therapeutics logo
PTC TherapeuticsPTCT
42.3%+27.4pp

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.4M-37.6%
Net income-$54.8M-38.8%
EPS (diluted)-$0.38+9.5%

Balance sheet

See full
Cash & equivalents$159.4M+14.7%
Total debt$20.2M-12.6%
Total equity$374.1M+44.8%
Total assets$420.6M+36.4%

Cash flow

See full
Operating cash flow-$52.6M-40.6%
CapEx$150.0K-60.2%
Free cash flow-$52.7M-39.6%

Valuation

See full
Market cap$857.5M+69.9%
Enterprise value$718.26M+84.8%

Profitability

See full
Operating margin-1,315.2%-4,060pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-65.5%-2.5pp
Debt / equity0.1×0.0×
Current ratio13.8×+4.5×

Where this comes from

Calculated from Solid Biosciences Inc.’s reported figures.

net income/total revenue=-1,062.3%

Based on trailing twelve months.

The source filing: Solid Biosciences Inc.’s 10-K, filed March 13, 2024. Open the filing →

Filed
Mar 13, 2024
Fiscal year
FY2023
Accession
0000950170-24-030508

FAQ

What is Solid Biosciences Inc.'s net margin?
Solid Biosciences Inc. (SLDB) reported net margin of -1,062.3% in Q4 2022.
How has Solid Biosciences Inc.'s net margin changed year-over-year?
Solid Biosciences Inc.'s net margin decreased by 100.4% year-over-year, from -530% to -1,062.3%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.

Ask your AI about Solid Biosciences Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude